Navigation Links
Khosla Cryo Multi With I/A System

ProductsKhosla Cryo Multi With I/A System
Company Khosla Medical & Surgical, Inc.
Item Khosla Cryo Multi With I/A System
Features 
  • Completely non-electric, foot-controlled, portable machine working with carbon-dioxide gas or nitrous oxide gas.
  • Suction variable from 0 - 300mm Hg. Surgeon can preset the required vacuum.
    • Description Provides quick freezing and instant defrosting by reversible flow of gas system - cleans the probes for every cycle automatically. Lightweight probe tips have high conductivity silver. Single footswitch for Cryo or I/A. The surgeon can select either of the two by a simple selector switch. Surgeon can have a selection of Irrigation, or Irrigation and Aspiration together with the double footswitch. Lightweight, autoclavable I/A hand-pieces available with 0.3mm and 0.5mm side aspiration ports. Useful for Cataract, Retinal Detachment, Glaucoma and Intra-vitreal surgery.
    Info Khosla Medical & Surgical, Inc.
    Customer Service: (408) 996 0205
    Web site: http://www.khosla-med.com/

    Related medicine products :

    1. Khosla Mini Non-Illuminated Trial Lens Set, With Lenses Mounted
    2. Khosla Non-Illuminated Trial Lens Set, With Lenses Mounted
    3. Khosla Binocular Indirect Ophthalmoscope
    4. Khosla Irrigation/Aspiration Vitrectomy Unit
    5. Khosla Vitrectomy Super Deluxe
    6. Khosla Irrigation Aspiration Unit
    7. Khosla Vitrectomy Super (Gas Operated)
    8. Khosla Phaco System
    9. Operating Microscope With Khosla Head
    10. Khosla Applanation Tonometer
    11. Khosla Slit Lamp Set
    Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR 28R 29 51761 1Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR 28R 29 51761 2Menopause Is More Than A Hot Flash 51759 1Menopause Is More Than A Hot Flash 51759 2Menopause Is More Than A Hot Flash 51759 3Menopause Is More Than A Hot Flash 51759 4Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 51757 1Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 51757 2Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 51757 3